tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Argenx price target raised to $887 from $880 at BofA

BofA raised the firm’s price target on Argenx (ARGX) to $887 from $880 and keeps a Buy rating on the shares after the company reported positive results from the Phase 3 SERON study evaluating Vyvgart in AChR- generalized myasthenia gravis patients last week. The firm, which models $6.4B in peak sales in gMG in 2034, notes that gMG now contributes $447 per share to its valuation of Argenx.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1